JP4618396B2 - Cleaning agent for toilet - Google Patents

Description

[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a solid drug for the purpose of scale control of a flush toilet drain pipe.
[0002]
In particular, the present invention relates to a medicine to be filled in an automatic medicine supply device that is branched and installed in a flush water pipe of a flush toilet.
[0003]
[Prior art]
As the scale generated on the inner surface of the drainage pipe accumulates, the water distribution pipe becomes clogged. In particular, since the removal of the scale generated in the toilet water pipe is troublesome, the generation of such a scale is prevented in advance.
[0004]
According to research on the scale generation of toilet water pipes, especially urinal water pipes, the enzyme acts on urea in the water pipes remaining in the drain pipes to decompose urea, and this decomposition produces ammonia. It has been elucidated that the residual wastewater becomes alkaline and the dissolved calcium content in the urine is finally deposited as a scale. And the method of preventing the production | generation of this scale by dissolving an acidic substance in waste water and maintaining this waste water acidic from the vicinity of neutrality is already known, and there are also many proposals regarding the improvement.
[0005]
In addition, an automatic drug injection device is installed in the middle of the pipe, and an acidic drug is filled in the automatic drug injection device and an acidic solution is injected into a toilet. These automatic injection devices are described in JP-A-3-59236, JP-A-3-66842, and the like.
[0006]
The drug to be filled in this automatic drug injection device is provided by melting a conventional water-soluble surfactant or a sublimable substance such as paradichlorobenzene, and cooling it with a readily soluble solid acid substance such as sulfamic acid. I have done it.
[0007]
[Problems to be solved by the invention]
In order to retain a readily soluble solid acid such as sulfamic acid for a long period of time, paradichlorobenzene and surfactants have been used as dissolution rate regulators in the past. However, paradichlorobenzene, an insoluble substance, is added to the composition. There is a risk of clogging the chemical injection pipe. In addition, a drug containing a surfactant as a main dissolution preparation may cause swelling, softening, cracking, etc. in water.
[0008]
The present invention does not use paradichlorobenzene or a surfactant as the main component of dissolution preparation, and has shape stability that does not cause swelling, softening, cracking, etc. even when used in water, and elutes a preferred acid in the water in contact However, the present invention intends to provide a solid drug exhibiting persistence.
[0009]
[Means for Solving the Problems]
The solid drug of the present invention contains 100 parts by weight of a solid acid having a particle size that passes through a 12-mesh sieve but does not pass through a 250-mesh sieve, and an acid having a particle size that passes through a 12-mesh sieve but does not pass through a 250-mesh sieve. It is a solid drug consisting of 5 to 2000 parts by weight of anhydride.
[0010]
Shape stability that does not cause swelling, softening, cracking, etc. even when used in water by using an acid anhydride with a particle size that passes through a 12-mesh sieve but does not pass through a 250-mesh sieve as the main ingredient for dissolution preparation In addition, it elutes a preferable acid in the water that comes into contact with it, and it shows durability. Then, 1 to 100 g of the solid acid can be eluted into the water per hour per 1000 cm ^{2 of} the surface area in contact with 20 ° C. water.
[0011]
DETAILED DESCRIPTION OF THE INVENTION
Examples of the solid acid used in the present invention include various solid acids from those having a high solubility in water to those having a low solubility, such as sulfamic acid, fumaric acid, adipic acid, o-phthalic acid, isophthalic acid, terephthalic acid, and succinic acid. , Maleic acid, boric acid, methylene succinic acid, benzoic acid, salicylic acid, isocyanuric acid, tartaric acid, malic acid, citric acid, glutaric acid, oxalic acid, ascorbic acid, nicotinic acid, aspartic acid, p-toluenesulfonic acid, gallic acid Hydroxyacetic acid, hydrocinnamic acid, DL-pyrrolidone-2-carboxylic acid, sodium hydrogen sulfate, glycolic acid, aluminum sulfate and the like. As this solid acid, a product having a solubility of 0.2 to 80% by weight with respect to 100 g of water at 20 ° C. is more preferable, and sulfamic acid, benzoic acid, malic acid, citric acid, oxalic acid, sodium hydrogensulfate, tartaric acid. , Succinic acid, and mixtures thereof. Particularly preferred are sulfamic acid, citric acid and succinic acid. In addition, a solid acid having a relatively high water solubility can be mixed and used.
[0012]
The solid acid is preferably a solid acid having a particle size that passes through a 12-mesh sieve but does not pass through a 250-mesh sieve. A solid acid having such a particle size can be obtained by subjecting the solid acid to operations such as grinding and sieving.
[0013]
Examples of the acid anhydride used in the present invention include succinic anhydride, maleic anhydride, phthalic anhydride, benzoic anhydride, isobutyric anhydride, itaconic anhydride, diglycolic anhydride, and toluic anhydride. And what has the solubility of 0.01 to 0.6 weight% with respect to 20 degreeC water is more preferable. In particular, succinic anhydride and phthalic anhydride are preferred.
[0014]
The acid anhydride is preferably an acid anhydride having a particle size that passes through a 12-mesh sieve but does not pass through a 250-mesh sieve. An acid anhydride having such a particle size can be obtained by subjecting the acid anhydride to operations such as grinding and sieving.
[0015]
And, with respect to 100 parts by weight of the solid acid having the above particle size, the acid anhydride having the above particle size is uniformly mixed to 5 to 2000 parts by weight, more preferably 10 to 1800 parts by weight, still more preferably 30 to 1000 parts by weight. The solid drug of the present invention is produced by tableting. The chemical | medical agent containing the amount of acid anhydrides more than 2000 weight part with respect to 100 weight part of solid acids cannot fully reduce the pH of the water which contacts this, and scale formation prevention effect is not enough. On the contrary, those containing an acid anhydride in an amount of less than 5 parts per 100 parts by weight of the solid acid have remarkable prevention of scale formation but cannot be maintained for a predetermined period. Moreover, there is a possibility that it cannot be molded.
[0016]
Further, a chelating agent can be added to the solid drug comprising a solid acid and an acid anhydride. Examples of the chelating agent include polyacrylic acid, polymethacrylic acid, polyitaconic acid, polymaleic acid, a copolymer of maleic acid and a compound having various vinyl groups, and a polymer compound such as polystyrene sulfonic acid. Polyacrylic acid is particularly preferable. And a chelating agent can add 1-100 weight part of a chelating agent with respect to 100 weight part of solid acids, More preferably, it is 5-80 weight part, More preferably, 10-60 weight part can be added.
[0017]
The chelating agent is preferably a chelating agent having a particle size that passes through a 12-mesh sieve but does not pass through a 250-mesh sieve. A chelating agent having such a particle size can be obtained by subjecting the chelating agent to operations such as grinding and sieving.
[0018]
In addition to the solid acid, acid anhydride, and chelating agent, the solid drug can contain a small amount of various conventionally used additives as desired. Examples of these additives include lubricants, bactericides, antifungal agents, corrosion inhibitors, pigments, fragrances, etc., and a solid drug is obtained from a mixture of the above-mentioned solid acid and acid anhydride and these desired additives. It is preferable to make it. Examples of the method for producing a solid drug include a method in which a solid acid, an acid anhydride and a desired additive in the above ratio are uniformly mixed and compression molded.
[0019]
【Example】
Example Tablet Molding Method Molded as a tablet. The solid acid, acid anhydride and other additives used were adjusted to a particle size that passed through a 12 mesh screen but not through a 250 mesh screen. The molding conditions were hydraulic powder compression molding, and a cylindrical molded body (tablet) having a diameter of about 30 mm and a thickness of about 15 to 16 mm was manufactured based on 15 g of one tablet according to the following formulation. The compression was performed using the above molding machine at a hydraulic pressure of 1000 kg / cm ² .
[0020]
Example 1
[0021]
[Table 1]
Formulation parts by weight Citric acid 100
Succinic anhydride 33.3
[0022]
According to this prescription, a solid drug was obtained by the tablet forming method.
[0023]
Example 2
[0024]
[Table 2]
Formulation Weight part Succinic acid 100
Succinic anhydride 500
[0025]
According to this prescription, a solid drug was obtained by the tablet forming method.
[0026]
Example 3
[0027]
[Table 3]
Formulation Weight part Succinic acid 100
Succinic anhydride 100
Polyacrylic acid ^{* 1)} 10
[0028]
* 1) Polyacrylic acid having a molecular weight of 5,000 to 6,000 was used.
[0029]
According to this prescription, a solid drug was obtained by the tablet forming method.
[0030]
Example 4
[0031]
[Table 4]
Formulation Weight part Succinic acid 100
Succinic anhydride 500
Polyacrylic acid ^{* 1)} 30
[0032]
According to this prescription, a solid drug was obtained by the tablet forming method.
[0033]
Example 5
[0034]
[Table 5]
Formulation parts by weight Sulfamic acid 100
Phthalic anhydride 100
[0035]
According to this prescription, a solid drug was obtained by the tablet molding method.
[0036]
Comparative Example 1
[0037]
[Table 6]
Formulation parts by weight Sulfamic acid 100
Paradichlorobenzene 33.3
Nonionic surfactant ^{* 2)} 33.3
[0038]
* 2) A nonionic active surfactant used was a copolymer of propylene oxide and ethylene oxide having a molecular weight of 20,000.
[0039]
According to this prescription, a solid drug was obtained by the tablet molding method.
[0040]
Comparative Example 2
[0041]
[Table 7]
Formulation parts by weight Citric acid 100
Boric acid 33.3
[0042]
According to this prescription, a solid drug was obtained by the tablet molding method.
[0043]
Experimental example 1
Using the solid medicines obtained in the examples and comparative examples, each agent was immersed in a beaker at 20 ° C., and the shape of the medicine in the beaker changed after 5 days, such as swelling and disintegration. When the presence or absence was observed, the results described in Table 1 were obtained.
[0044]
[Table 8]
Table 1
Drug Drug shape Example 1 No change Example 2 No change Example 3 No change Example 4 No change Example 5 No change Comparative Example 1 Swelling
Comparative Example 2 Collapse
[0045]
Table 1 shows that when the solid drug of the present invention is immersed in water, neither swelling nor disintegration occurs, but the solid drug product of Comparative Examples 1 and 2 causes swelling or disintegration. ing.
[0046]
【The invention's effect】
The solid drug, which is a toilet cleaning drug of the present invention, passes 100 parts of solid acid having a particle size that passes through a 12-mesh sieve but not through a 250-mesh sieve, and passes through a 12-mesh sieve but a 250-mesh sieve. It is a solid drug consisting of 5 to 2000 parts by weight of acid anhydride having a particle size that does not pass. Shape stability that does not cause swelling, softening, cracking, etc. even when used in water by using an acid anhydride of a particle size that passes through a 12-mesh sieve but does not pass through a 250-mesh sieve as the main ingredient for dissolution preparation In addition, it is possible to elute a preferable acid in the water in contact with it, and to show durability.

Claims (5)

100 parts by weight of citric acid as a solid acid having a particle size that passes through a 12-mesh sieve but not through a 250-mesh sieve, and anhydrous succinate as an acid anhydride having a particle size that passes through a 12-mesh sieve but does not pass through a 250-mesh sieve A toilet cleaning agent, which is a solid agent comprising 5 to 2000 parts by weight of an acid . 100 parts by weight of succinic acid as a solid acid having a particle size that passes through a 12-mesh sieve but not through a 250-mesh sieve, and succinic anhydride as an acid anhydride having a particle size that passes through a 12-mesh sieve but does not pass through a 250-mesh sieve A toilet cleaning agent, which is a solid agent comprising 5 to 2000 parts by weight of an acid . 100 parts by weight of sulfamic acid as a solid acid having a particle size that passes through a 12-mesh sieve but not through a 250-mesh sieve, and phthalic anhydride as an acid anhydride having a particle size that passes through a 12-mesh sieve but does not pass through a 250-mesh sieve A toilet cleaning agent, which is a solid agent comprising 5 to 2000 parts by weight of an acid . The toilet cleaning agent according to any one of claims 1 to 3, further comprising a chelating agent. The toilet cleaning agent according to claim 4 , wherein the chelating agent is polyacrylic acid.